Applying New Stem Cell Science to Reboot the Immune System

Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. By creating a platform focused on key areas of transplant medicine, Magenta Therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit.

Year Invested: 2016
Location: Cambridge, Mass.

Recent News

December 2, 2016
Magenta Therapeutics Cofounder David Scadden Honored at the American Society of Hematology Annual Meeting, as Scientific Founders Present New Stem Cell Biology Data

November 16, 2016
Magenta Therapeutics Announces $48.5M Series A Financing to Transform Stem Cell Transplant for Immune and Blood Diseases

Read More News

Associated Team Members

Alexis Borisy